Using 3D modeling technology from CTIBiotech, BASF has demonstrated ex-vivo production of physiological sebum and regulation of the sebum through active ingredients. The technology could prove significant in the testing of active ingredients in skin care, as well as the study of how sebaceous glands function in relation to a host of age-related, inflammatory, and microbial skin disorders.
“Compared to current in vitro methods, the 3D models developed by CTIBiotech allow analysis more in touch with human physiology and sebaceous gland metabolism,” said Dr. Sabine Pain, BASF’s project lead. “That’s how their technology helps us accelerate the development of innovative and highly reliable ingredients for the skin care market. Our understanding of sebaceous gland metabolism provides the basis for developing and testing advanced cosmetic bio-actives for skincare applications, and in particular skincare products for oily skin.”
CTIBiotech is equally enthusiastic about the study’s findings and potential impact on future research. Said chief science officer and president Colin McGuckin: “Because of their experience and expertise in developing solutions for the dermo-cosmetics market, BASF understands the benefits of collaborating with tissue engineering experts. The next evolution of the sebaceous gland model will be based on a 3D bio-printing technology that allows us to fully reproduce micro-glands into a full thickness skin model, in vitro.”